Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study

Author： Tanaka Yoshihiro   Yoshida Kazuhiro   Sanada Yuichi   Osada Shinji   Yamaguchi Kazuya   Takahashi Takao  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.66, Iss.6, 2010-11, pp. : 1159-1165

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck

By Tsukuda Mamoru   Mikami Yasukazu   Tanigaki Yuji   Katori Hideaki   Horiuchi Choichi   Ikeda Yoichi   Taguchi Takahide   Ono Machiko   Yoshida Takahumi   Sakuma Yasunori   Aikoh Ken  

International Journal of Clinical Oncology, Vol. 9, Iss. 3, 2004-06 ,pp. : 161-166

Springer Publishing Company

Access to resources Recommend Favorite

Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation

By Yoshioka Takashi   Sakayori Masato   Kato Shunsuke   Chiba Natsuko   Miyazaki Shukichi   Nemoto Kenji   Shibata Hiroyuki   Shimodaira Hideki   Ohtsuka Kazunori   Kakudo Yuichi   Sakata Yuh   Ishioka Chikashi  

International Journal of Clinical Oncology, Vol. 11, Iss. 6, 2006-12 ,pp. : 454-460

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma

By Lee Jeeyun   Im Young-Hyuck   Cho Eun   Hong Yong   Lee Hyo   Kim Hyo   Kim Mi-Jin   Kim Kwhanmien   Kang Won   Park Keunchil   Shim Young  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 77-84

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer

By Marshall John   Shapiro Geoffrey I   Uttenreuther-Fischer Martina   Ould-Kaci Mahmoud   Stopfer Peter   Gordon Michael S  

Future Oncology, Vol. 9, Iss. 2, 2013-02 ,pp. : 271-281

Future Medicine

Access to resources Recommend Favorite

Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

By Katori Hideaki   Tsukuda Mamoru   Watai Kiichi  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 3, 2007-08 ,pp. : 399-406

Springer Publishing Company

Access to resources Recommend Favorite